Clinical Trials Logo

Allergic Conjunctivitis clinical trials

View clinical trials related to Allergic Conjunctivitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06293820 Recruiting - Clinical trials for Allergic Conjunctivitis

A Study Of TL-925 For The Treatment of AC

Start date: March 2024
Phase: Phase 2
Study type: Interventional

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

NCT ID: NCT06153342 Recruiting - Clinical trials for Allergic Conjunctivitis

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Start date: November 2023
Phase: Phase 2
Study type: Interventional

In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

NCT ID: NCT05969236 Recruiting - Clinical trials for Allergic Conjunctivitis

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults

Start date: October 6, 2023
Phase: Phase 1
Study type: Interventional

The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants. Participants will receive either of the following treatment: - MDI-1228_mesylate Ophthalmic Solution, or - Placebo** Researchers will observe any changes in heath (if any) in participants receiving the study treatment to evaluate the safety and tolerability*** of the study drug. Researchers will also collect several blood samples from participants to study PK profiles of the drug. Note: - PK profiles: how the drug interacts with the body. **placebo: a harmless substance that contains no active agents. ***tolerability: how well you can tolerate the drug.

NCT ID: NCT05839938 Recruiting - Clinical trials for Allergic Conjunctivitis

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

Start date: August 8, 2022
Phase: N/A
Study type: Interventional

A double-blind study to evaluate the role of vitamin D in corneal epithelial barrier function, ocular microbiome, ocular inflammation, and visual acuity of children with allergic conjunctivitis.

NCT ID: NCT04198740 Recruiting - Dry Eye Syndrome Clinical Trials

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface

EML-MSO
Start date: February 1, 2020
Phase:
Study type: Observational

This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.